Published in J Clin Oncol on April 26, 2010
Matching Patients With Hematologic Malignancy to Adequate Clinical Trials | NCT02758080
Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov (2010) 4.66
Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol (2011) 4.12
Targeted therapies for breast cancer. J Clin Invest (2011) 2.22
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol (2012) 2.06
Antibody-based therapeutics to watch in 2011. MAbs (2011) 2.00
Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc Natl Acad Sci U S A (2012) 1.99
HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther (2011) 1.92
Strategies for modern biomarker and drug development in oncology. J Hematol Oncol (2014) 1.89
Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer Biol Ther (2011) 1.84
Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncog (2012) 1.75
High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)--mediated inhibition of platelet production. Blood (2012) 1.73
Envisioning the future of early anticancer drug development. Nat Rev Cancer (2010) 1.67
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol (2012) 1.57
Targeted estrogen delivery reverses the metabolic syndrome. Nat Med (2012) 1.51
Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res (2011) 1.39
New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available. Clin Cancer Res (2011) 1.26
Treating breast cancer in the 21st century: emerging biological therapies. J Cancer (2013) 1.26
Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treat Rev (2012) 1.23
Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. Mol Cancer Ther (2010) 1.19
Drug-conjugated antibodies for the treatment of cancer. Br J Clin Pharmacol (2013) 1.18
Bispecific digoxigenin-binding antibodies for targeted payload delivery. Proc Natl Acad Sci U S A (2011) 1.15
Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer. Br J Cancer (2012) 1.12
Mechanism-based cancer therapy: resistance to therapy, therapy for resistance. Oncogene (2014) 1.10
Cancer radioimmunotherapy. Immunotherapy (2011) 1.10
Treatment of HER2-positive breast cancer. Breast (2013) 1.09
Site-specific coupling and sterically controlled formation of multimeric antibody fab fragments with unnatural amino acids. J Mol Biol (2011) 1.08
Immunoconjugates and long circulating systems: origins, current state of the art and future directions. Adv Drug Deliv Rev (2012) 1.05
Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease. Curr Opin Obstet Gynecol (2011) 1.03
ADME of antibody-maytansinoid conjugates. AAPS J (2012) 1.03
Prodrugs for improving tumor targetability and efficiency. Adv Drug Deliv Rev (2011) 1.00
Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer. Clin Pharmacol Ther (2012) 0.98
Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer. Breast Cancer (Dove Med Press) (2014) 0.97
Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance. J Carcinog (2011) 0.96
Trastuzumab. Oncologist (2011) 0.95
Phenotypic and Molecular Characterization of MCF10DCIS and SUM Breast Cancer Cell Lines. Int J Breast Cancer (2013) 0.94
Microtubule inhibitor-based antibody-drug conjugates for cancer therapy. Onco Targets Ther (2014) 0.93
Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer. Int J Breast Cancer (2012) 0.92
Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. Ann Oncol (2011) 0.92
Breast cancer in 2010: Novel targets and therapies for a personalized approach. Nat Rev Clin Oncol (2011) 0.92
Targeted therapy in HER2-positive breast cancer. Biomed Rep (2013) 0.91
Gene status in HER2 equivocal breast carcinomas: impact of distinct recommendations and contribution of a polymerase chain reaction-based method. Oncologist (2014) 0.91
Evolving therapies and FAK inhibitors for the treatment of cancer. Anticancer Agents Med Chem (2010) 0.90
Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer. Mol Med (2013) 0.90
Fourth World Antibody-Drug Conjugate Summit: February 29-March 1, 2012, Frankfurt, Germany. MAbs (2012) 0.90
Breast cancer brain metastases: new directions in systemic therapy. Ecancermedicalscience (2013) 0.89
Targeted Therapies in Breast Cancer: Implications for Advanced Oncology Practice. J Adv Pract Oncol (2015) 0.89
Combinatorial effect of maytansinol and radiation in Drosophila and human cancer cells. Dis Model Mech (2011) 0.88
8(th) Annual European Antibody Congress 2012: November 27-28, 2012, Geneva, Switzerland. MAbs (2013) 0.88
Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components. Toxins (Basel) (2011) 0.87
Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates. Ann Transl Med (2014) 0.86
The potential for trastuzumab emtansine in human epidermal growth factor receptor 2 positive metastatic breast cancer: latest evidence and ongoing studies. Ther Adv Med Oncol (2012) 0.86
Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases. J Control Release (2012) 0.85
Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates. Cancer Chemother Pharmacol (2014) 0.84
Bioorthogonal, two-component delivery systems based on antibody and drug-loaded nanocarriers for enhanced internalization of nanotherapeutics. Biomaterials (2013) 0.84
Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer. Therap Adv Gastroenterol (2012) 0.83
Combining emerging agents in advanced breast cancer. Oncologist (2011) 0.83
Drug conjugates such as Antibody Drug Conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice. Int J Mol Sci (2012) 0.83
Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential. Ther Adv Med Oncol (2014) 0.83
Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine. Cancer Manag Res (2016) 0.83
Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer. Crit Rev Oncol Hematol (2010) 0.83
Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates. Pharm Res (2014) 0.83
Linked-in: design and efficacy of antibody drug conjugates in oncology. Oncotarget (2013) 0.82
Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer. Future Oncol (2013) 0.82
Advances and future directions in the targeting of HER2-positive breast cancer: implications for the future. Curr Treat Options Oncol (2014) 0.82
Modified bleomycin disaccharides exhibiting improved tumor cell targeting. Biochemistry (2014) 0.81
Changing strategies for target therapy in gastric cancer. World J Gastroenterol (2016) 0.81
Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3. Hum Vaccin Immunother (2015) 0.81
Trends in translational medicine and drug targeting and delivery: new insights on an old concept-targeted drug delivery with antibody-drug conjugates for cancers. J Pharm Sci (2013) 0.80
Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine. Pharmgenomics Pers Med (2014) 0.80
Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials. J Ocul Pharmacol Ther (2015) 0.79
Current targeted therapies in breast cancer: clinical applications in the elderly woman. Oncologist (2011) 0.78
Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies. MAbs (2014) 0.78
New developments in the treatment of HER2-positive breast cancer. Breast Cancer (Dove Med Press) (2012) 0.78
Regulation of Apoptosis by HER2 in Breast Cancer. J Carcinog Mutagen (2013) 0.78
Challenges and advances in the assessment of the disposition of antibody-drug conjugates. Biopharm Drug Dispos (2015) 0.78
Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling. Oncotarget (2015) 0.77
In vitro and in vivo application of anti-cotinine antibody and cotinine-conjugated compounds. BMB Rep (2014) 0.76
Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs. J Clin Pharmacol (2015) 0.76
Role of trastuzumab in the management of HER2-positive metastatic breast cancer. Breast Cancer (Dove Med Press) (2010) 0.76
Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy. AAPS J (2016) 0.76
The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease. Br J Pharmacol (2016) 0.76
AGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011. Breast Care (Basel) (2011) 0.75
Emerging therapies for breast cancer. J Hematol Oncol (2017) 0.75
Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients. Breast Cancer (Dove Med Press) (2014) 0.75
Tissue distribution and tumor uptake of folate receptor-targeted epothilone folate conjugate, BMS-753493, in CD2F1 mice after systemic administration. Acta Pharm Sin B (2016) 0.75
Emerging targeted combinations in the management of breast cancer. Breast Cancer (Dove Med Press) (2013) 0.75
Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy. MAbs (2016) 0.75
Ado-Trastuzumab Emtansine in Metastatic HER2-Positive Breast Cancer. J Adv Pract Oncol (2014) 0.75
Safety and efficacy of the combination of T-DM1 with radiotherapy of the central nervous system in a patient with HER2-positive metastatic breast cancer: case study and review of the literature. Ecancermedicalscience (2015) 0.75
State of the art in anti-cancer mAbs. J Biomed Sci (2017) 0.75
Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: a Meta-analysis. Sci Rep (2016) 0.75
HER2 expression and efficacy of T-DM1. Breast Cancer Res (2014) 0.75
Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013. Drug Des Devel Ther (2016) 0.75
Application of meta- and para-Phenylenediamine as Enhanced Oxime Ligation Catalysts for Protein Labeling, PEGylation, Immobilization, and Release. Curr Protoc Protein Sci (2015) 0.75
Expanding the Reach of Antibody-Drug Conjugates. ACS Med Chem Lett (2016) 0.75
Ado-trastuzumab emtansine and radium 223 dichloride. Hosp Pharm (2013) 0.75
Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens. Br J Clin Pharmacol (2017) 0.75
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med (2011) 13.74
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48
Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science (2009) 10.78
Regulation of cellular metabolism by protein lysine acetylation. Science (2010) 10.55
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol (2007) 9.29
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell (2004) 8.18
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell (2006) 6.15
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell (2004) 6.12
Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell (2009) 6.02
Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol (2008) 5.98
PTEN-mediated apical segregation of phosphoinositides controls epithelial morphogenesis through Cdc42. Cell (2007) 5.84
Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction. Cell (2010) 5.73
Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem (2002) 5.63
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol (2008) 5.54
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res (2008) 5.34
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2013) 5.21
A navigator for human genome epidemiology. Nat Genet (2008) 5.07
An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell (2003) 5.06
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol (2011) 4.77
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol (2008) 4.68
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol (2010) 4.62
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell (2002) 4.34
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol (2012) 4.19
Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol (2011) 4.12
Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol (2005) 4.02
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst (2007) 3.95
A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res (2008) 3.93
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol (2008) 3.58
Development and validation of a CGH microarray for clinical cytogenetic diagnosis. Genet Med (2005) 3.39
The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res (2012) 3.36
Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res (2006) 3.34
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov (2013) 2.88
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.86
Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol (2010) 2.84
Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst (2005) 2.74
Defective cardiovascular development and elevated cyclin E and Notch proteins in mice lacking the Fbw7 F-box protein. Proc Natl Acad Sci U S A (2004) 2.66
Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell (2004) 2.60
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat (2010) 2.55
Calorie restriction and SIRT3 trigger global reprogramming of the mitochondrial protein acetylome. Mol Cell (2012) 2.54
Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol (2009) 2.53
Circadian clock NAD+ cycle drives mitochondrial oxidative metabolism in mice. Science (2013) 2.49
Protein aggregation and bioprocessing. AAPS J (2006) 2.47
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol (2012) 2.43
Phosphatidylinositol-3,4,5-trisphosphate regulates the formation of the basolateral plasma membrane in epithelial cells. Nat Cell Biol (2006) 2.39
Tracking the epidemiology of human genes in the literature: the HuGE Published Literature database. Am J Epidemiol (2006) 2.34
Epithelial polarity and tubulogenesis in vitro. Trends Cell Biol (2003) 2.31
Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res (2009) 2.30
Sirt3 promotes the urea cycle and fatty acid oxidation during dietary restriction. Mol Cell (2011) 2.29
Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta (2011) 2.21
Genome-wide association studies, field synopses, and the development of the knowledge base on genetic variation and human diseases. Am J Epidemiol (2009) 2.15
A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell (2011) 2.14
Cell-polarity dynamics controls the mechanism of lumen formation in epithelial morphogenesis. Curr Biol (2008) 2.13
Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer. Nucl Med Commun (2013) 2.12
Oncogenic ERBB3 mutations in human cancers. Cancer Cell (2013) 2.06
Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. Mol Cancer Ther (2012) 2.03
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol (2005) 1.99
Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer Res (2010) 1.98
Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother (2005) 1.98
Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors. Cancer Biol Ther (2010) 1.94
Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. J Clin Oncol (2008) 1.93
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol (2007) 1.93
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther (2013) 1.90
Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy. Clin Cancer Res (2013) 1.89
The associations between race and geographic area and quality-of-care indicators in patients approaching ESRD. Clin J Am Soc Nephrol (2013) 1.87
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res (2009) 1.79
The SOX2 response program in glioblastoma multiforme: an integrated ChIP-seq, expression microarray, and microRNA analysis. BMC Genomics (2011) 1.79
High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)--mediated inhibition of platelet production. Blood (2012) 1.73
Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin Cancer Res (2009) 1.70
Cancer GAMAdb: database of cancer genetic associations from meta-analyses and genome-wide association studies. Eur J Hum Genet (2011) 1.69
Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol (2009) 1.66
Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol (2002) 1.66
Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res (2011) 1.66
Managed care, hospice use, site of death, and medical expenditures in the last year of life. Arch Intern Med (2002) 1.65
Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res (2010) 1.63
Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: Report of 39 cases and review of the literature. J Bone Miner Res (2012) 1.63
A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin Pharmacol Ther (2002) 1.63
Morphological and biochemical analysis of Rac1 in three-dimensional epithelial cell cultures. Methods Enzymol (2006) 1.59
Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J Clin Oncol (2011) 1.58
Age structure changes and extraordinary lifespan in wild medfly populations. Aging Cell (2008) 1.57
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol (2012) 1.57
Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations. Clin Cancer Res (2012) 1.56
Conditional mutagenesis of the murine serum response factor gene blocks cardiogenesis and the transcription of downstream gene targets. J Biol Chem (2005) 1.56
Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer. J Clin Oncol (2010) 1.56
Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. Clin Cancer Res (2012) 1.50
PPM1H is a p27 phosphatase implicated in trastuzumab resistance. Cancer Discov (2011) 1.50
Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. Clin Cancer Res (2011) 1.49
Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. J Clin Oncol (2012) 1.48
Nudel functions in membrane traffic mainly through association with Lis1 and cytoplasmic dynein. J Cell Biol (2004) 1.47
Subepicardial endothelial cells invade the embryonic ventricle wall to form coronary arteries. Cell Res (2013) 1.46